Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (511-520 of 560) with videos related to

Pageof 56
Sort By:
Cancer Research|September 14, 2011
FOXO3a-Dependent Mechanism of E1A-Induced ChemosensitizationJen-Liang Su, Xiaoyun Cheng, Hirohito Yamaguchi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 21, 2015
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor MarkersGyörgy Sölétormos, Michael J Duffy, Suher Othman Abu Hassan, et al.
Gynecologic Oncology|August 25, 2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancerM L Donato, D M Gershenson, J T Wharton, et al.
BMC Medicine|May 20, 2024
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancerJing Guo, Chunyan Wang, Ning Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapyLynn C Hartmann, Karen H Lu, Gerald P Linette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Bone Marrow Transplantation|May 4, 2004
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantationM L Donato, A Aleman, R E Champlin, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Cancer Cell|August 17, 2010
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerAhmed Ashour Ahmed, Zhen Lu, Nicholas B Jennings, et al.
Pageof 56

Showing results (511-520 of 560) with videos related to

Sort By:
Pageof 56
Cancer Research|September 14, 2011
FOXO3a-Dependent Mechanism of E1A-Induced ChemosensitizationJen-Liang Su, Xiaoyun Cheng, Hirohito Yamaguchi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 21, 2015
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor MarkersGyörgy Sölétormos, Michael J Duffy, Suher Othman Abu Hassan, et al.
Gynecologic Oncology|August 25, 2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancerM L Donato, D M Gershenson, J T Wharton, et al.
BMC Medicine|May 20, 2024
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancerJing Guo, Chunyan Wang, Ning Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapyLynn C Hartmann, Karen H Lu, Gerald P Linette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Bone Marrow Transplantation|May 4, 2004
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantationM L Donato, A Aleman, R E Champlin, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Cancer Cell|August 17, 2010
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerAhmed Ashour Ahmed, Zhen Lu, Nicholas B Jennings, et al.
Pageof 56